A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples